Briggs Morrison - 13 Mar 2023 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role: President, Head of R&D, Director
Signature: /s/ Michael A. Metzger, Attorney-in-fact
Issuer symbol: SNDX
Transactions as of: 13 Mar 2023
Net transactions value: -$853,465
Form type: 4
Filing time: 14 Mar 2023, 16:42:48 UTC
Previous filing: 09 Mar 2023
Next filing: 12 Apr 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SNDX	Common Stock	Options Exercise	$337,209	+52,854	+296%	$6.38	70,690	13 Mar 2023	Direct
transaction	SNDX	Common Stock	Sale	$1,190,674	-52,854	-75%	$22.53	17,836	13 Mar 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SNDX	Stock Option (Right to Buy)	Options Exercise	$0	-52,854	-100%	$0.000000^*	0	13 Mar 2023	Common Stock	52,854	$6.38	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 822,000 options to purchase shares of common stock that are vested and immediately exercisable and a total of 302,146 options to purchase shares of common stock that have not yet vested.
F2	The sale prices ranged from $22.05 to $23.10.
F3	This option is fully vested.